Skip to main content
. 2015 Nov 7;17:79–86. doi: 10.1007/s40257-015-0161-5

Fig. 1.

Fig. 1

PASI75, PASI90, and PASI100 response rates overall and by experience with prior systemic therapies at a 4 weeks and b 16 weeks. Patients from Study M02-528 were excluded from the analysis at 16 weeks because it was a 12-week study. PASI75, PASI90, and PASI100 improvement of ≥75, ≥90, and 100 % from baseline, respectively, in the Psoriasis Area and Severity Index score. *p < 0.001 compared with placebo